Commentary

Vulvar Inflammatory Dermatoses: New Approaches for Diagnosis and Treatment

Author and Disclosure Information

 

References

Plasma Cell Vulvitis

Plasma cell vulvitis is a chronic inflammatory disorder with an unknown etiology that some consider to be a variant of VLP.23 Others have observed an overlap with desquamative inflammatory vaginitis, categorizing PCV as a hemorrhagic vestibulovaginitis.24 Although its classification as a distinct entity remains under scrutiny, studies indicate a predilection for the nonkeratinized or partially keratinized vulva. A systematic review outlining common clinical findings reported that the most common anatomic sites included the vulvar vestibule, periurethral area, and labia minora.23 Additionally, reports have emphasized the association between PCV and other inflammatory vulvar skin conditions, including LS.25

Clinical Variants of PCV—A retrospective review proposed 2 clinical phenotypes for PCV: (1) primary non–lichen-associated PCV and (2) secondary lichen-associated PCV, which is linked to LS.26 The primary form is reported to be restricted to the vestibule, and the authors considered this a vulvar counterpart of atrophic vaginitis due to estrogen deficiency (now known as postmenopausal genitourinary syndrome). The secondary phenotype more commonly involved the vestibular and extravestibular epithelium.26

Management of PCV—Recognizing PCV in the context of LS may be important for identifying comorbid conditions and guiding treatment. However, evidence-based guidelines for PCV treatment are lacking. Commonly reported treatment modalities include clobetasol ointment 0.05% and tacrolimus ointment 0.1%.23 Successful treatment with hydrocortisone suppositories alternating with estradiol vaginal cream was reported in a recent case series.27 Crisaborole also has been reported as a treatment in 1 case of PCV.28 A recent case report found abrocitinib to be effective for the treatment of plasma cell balanitis in the setting of male genital LS,29 but there are limited data on the use of JAK inhibitors for PCV. Further research is necessary to ascertain the incidence, prevalence, clinical subtypes, and optimal management strategies for PCV to effectively treat patients with this condition.

Recommended Reading

Study Links Newer Shingles Vaccine to Delayed Dementia Diagnosis
MDedge Dermatology
Risk of MACE Comparable Among Biologic Classes for Psoriasis, PsA
MDedge Dermatology
Pilot Study Finds Experimental CBD Cream Decreases UVA Skin Damage
MDedge Dermatology
Study Finds Gout Drug Effective for Aphthous Ulcers in Children
MDedge Dermatology
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
MDedge Dermatology
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer Care
MDedge Dermatology
Psychiatric, Autoimmune Comorbidities Increased in Patients with Alopecia Areata
MDedge Dermatology
Case Series: Upadacitinib Effective for Granulomatous Cheilitis
MDedge Dermatology
Can Addressing Depression Reduce Chemo Toxicity in Older Adults?
MDedge Dermatology
Immunotherapy May Be Overused in Dying Patients With Cancer
MDedge Dermatology